RARE fungal species Aspergillus steynii previously not documented as a human pathogen has been identified in the first ever known case in humans. The breakthrough discovery provides new insight into the potential risks posed by emerging fungal infections and highlights the importance of advanced diagnostic approaches for vulnerable patient populations.
A new case report documents a 47-year-old woman who developed a pulmonary infection following immunosuppression after bone marrow transplantation. Through culture techniques, microscopy, mass spectrometry, molecular identification, and whole-genome sequencing, the team successfully identified A. steynii as the causative pathogen.
Genomic Analysis Reveals Resistance-Associated Features in Newly Identified Fungal Pathogen
The researchers conducted whole-genome analysis to better understand the characteristics of the fungal strain and its relationship with other pathogenic Aspergillus species. The analysis revealed a high degree of genomic similarity with other clinically important fungi and identified 470 unique gene families, many of which were linked to ABC transporter pathways associated with multidrug resistance.
Antifungal susceptibility testing showed that the strain remained sensitive to triazoles and echinocandins but demonstrated increased minimum inhibitory concentrations for several commonly used antifungal treatments, including amphotericin B, flucytosine, and fluconazole. The identification of potential resistance-associated genes raises important considerations for future monitoring and therapeutic approaches.
Discovery Highlights Growing Need for Surveillance of Emerging Aspergillus Infections
The findings represent the first confirmed evidence that A. steynii can infect humans, expanding understanding of the clinical impact of rare Aspergillus species. As fungal infections continue to emerge as a growing global health concern, identifying previously unrecognised pathogens is essential for improving diagnosis, treatment strategies, and patient outcomes.
According to the researchers, the emergence of A. steynii as a human pathogen presents new clinical challenges, including the risk of misdiagnosis, delayed treatment, and potential cross-species transmission. The discovery reinforces the need for improved surveillance and rapid identification methods, particularly among immunocompromised patients who may be at greater risk of severe infection.
Reference
Wang R et al. First report of human infection caused by Aspergillus steynii and analysis of its whole-genome characteristics. Case Rep Transbound Emerg Dis. 2026;2026: e4093308. DOI:10.1155/tbed/4093308.
Featured Image: arcyto on Adobe Stock
- Author:
